<DOC>
	<DOCNO>NCT02624960</DOCNO>
	<brief_summary>This single-arm , multi-center , open-label control study ass safety performance Accucinch System induce leave ventricular reverse remodel reduce severity functional mitral regurgitation symptomatic adult patient mitral regurgitation leave ventricular remodel due dilate cardiomyopathy ( ischemic non-ischemic etiology ) , high operative risk .</brief_summary>
	<brief_title>Safety Performance Accucinch System</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Study patient adult legal consent age Severity FMR : ≥ Moderate Ejection Fraction : ≥20 ≤60 % Symptom Status : NYHA IIIVa Treatment compliance optimal guideline direct medical therapy heart failure least 1 month Surgical risk : Subject eligible cardiac surgery Patients significant organic mitral valve pathology ( e.g . myxomatous degeneration , mitral valve prolapse flail leaflet ) Myocardial infarction percutaneous cardiovascular intervention , cardiovascular surgery , carotid surgery within 30 day Prior surgical , transcatheter , percutaneous mitral valve intervention Untreated clinically significant coronary artery disease require revascularization Hemodynamic instability : Hypotension requirement inotropic support mechanical hemodynamic support Any plan cardiac surgery intervention within next 6 month NYHA class IVb ( i.e. , nonambulatory ) ACC/AHA Stage D heart failure Fixed pulmonary artery systolic pressure &gt; 70 mmHg Severe tricuspid regurgitation Modified Rankin Scale ≥ 4 disability Hypertrophic cardiomyopathy , restrictive cardiomyopathy , constrictive pericarditis , structural heart disease cause heart failure dilate cardiomyopathy either ischemic nonischemic etiology Mitral valve area le 4.0 cm2 Anatomical pathology/constraints prevent appropriate access/implant GDS Accucinch System Renal insufficiency Mitral annular calcification Moderate severe aortic valve stenosis regurgitation aortic valve prosthesis Fluoroscopic echocardiographic evidence severe aortic arch calcification , mobile aortic atheroma , intracardiac mass , thrombus vegetation Active bacterial endocarditis History stroke within prior 3 month Subjects anticoagulation contraindicate Anemia Thrombocytopenia thrombocytosis Bleeding disorder hypercoaguable state Active peptic ulcer active gastrointestinal bleeding Known allergy nitinol , polyester , polyethylene Any prior true anaphylactic reaction contrast agent ; define know anaphylactoid nonanaphylactic allergic reaction contrast agent adequately premedicated prior index procedure . Life expectancy &lt; 1 year due noncardiac condition Currently participate another interventional investigational study Implant revision rhythm management device implantable cardioverter defibrillator within prior month Absence CRT class I indication criterion biventricular pace Subjects high dose steroid immunosuppressant therapy Female subject pregnant , child bear potential lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>